ReviewFrontiers in cardiovascular medicine2026
Inflammatory drivers of carotid atherosclerosis: signaling pathways, immune cells, and plaque stability.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carotid atherosclerosis (CAS; herein referring to carotid atherosclerotic disease, to be distinguished from carotid artery stenting, which shares the same abbreviation) is a primary driver of ischemic stroke, with inflammation playing a central role in its pathogenesis from plaque initiation to rupture. However, the complex regulatory network governing this inflammatory process remains to be fully elucidated. Purpose: This review comprehensively reviews the molecular and cellular inflammatory mechanisms underlying CAS, focusing on key signaling pathways, inflammatory mediators, and immune cell populations, to identify potential targets for therapeutic intervention. As a narrative review, it does not follow a formal systematic-search protocol. Key findings: We delineate the hierarchical activation of core signaling cascades-including the central NF-κB pathway, the MAPK and JAK/STAT modules, and the NLRP3 inflammasome-which collectively orchestrate a pro-inflammatory milieu. This network drives the expression of critical mediators (e.g., TNF-α, IL-1β, MMPs) and sculpts the behavior of lesional immune cells. Specifically, the imbalance between pro-inflammatory M1 macrophages together with Th1/Th17 effector T cells, vs. anti-inflammatory M2 macrophages and Tregs emerges as a key determinant of plaque stability. Conclusion: and Implications: The pathogenesis of CAS is governed by an intricate, multi-level inflammatory network. A detailed understanding of this network, particularly the crosstalk between signaling pathways and immune cell plasticity, provides a rationale for novel precision therapies. Targeting specific nodes within this network, rather than broad immunosuppression, holds promise for stabilizing high-risk plaques and reducing the burden of cerebrovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.